Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Metabolism of GLPG3970 in Healthy Males
NCT04907149Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- Jun 2021
- Primary completion
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of GLPG3970 in psoriasis, rheumatoid arthritis (RA) and ulcerative colitis (UC) (2 arms), sponsored by Galapagos NV. Primary endpoints: Absolute oral bioavailability of GLPG3970, Recovery of total radioactivity excreted in urine expressed as a percentage of the administered dose and 1 more. Started Jun 2021; status: completed.
02
Drugs
GLPG3970
03
Conditions
psoriasisrheumatoid arthritis (RA)ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT04907149.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04907149.